AstraZeneca’s candidate breast cancer therapy Enhertu received a fourth Breakthrough Therapy Designation from the U.S. Food and Drug Administration after the health regulator issued another BTD based on a Phase III trial presented at the European Society for Medical Oncology Congress 2021.
Lung Cancer Breakthroughs Touted at ESMO 2021
AstraZeneca, Clinical Data, Clinical Trials, Daiichi Sankyo, EGFR tyrosine kinase inhibitors (TKI), European Society for Medical Oncology (ESMO), Janssen, KRAS Mutations, Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-Based Chemotherapy, R&D, Regeneron Pharmaceuticals, Sanofi, Therapeutics, Topline DataCompanies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.
A combination of Mirati Therapeutics Inc.’s genetic mutation-targeting adagrasib and Eli Lilly and Co.’s older cancer drug Erbitux shrank tumors in 39 percent of patients with advanced colorectal cancer treated in a small trial, the company said on Sept. 19.
Non-small cell lung cancer (NSCLC) is one of the most devestating diagnoses and highest unmet needs in the oncology space. EQRx, which intends to solve pricing and access challenges for patients, unveiled new data at the European Society for Medical Oncology (ESMO) Congress 2021 showing that it might just have the answer to NSCLC too.
Biopharma companies big and small presented exciting clinical studies at the European Society for Medical Oncology Congress 2021.
AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial
Analysis, Blockbusters, Central Nervous System, Clinical Data, Clinical Trials, Disease-Free Survival (DFS), Epidermal Growth Factor Receptor-Mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC), European Society for Medical Oncology (ESMO), R&D, TherapeuticsAstraZeneca released new results from the company’s ADAURA Phase III trial showing that Tagrisso (osimertinib) demonstrated clinically meaningful improvement in central nervous system disease-free survival in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC), after complete tumor resection.
Roche company Genentech presented data from three Phase III trials of Tecentriq (atezolizumab) in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
ESMO News: AstraZeneca, Merck, Janssen, Amgen and More
Basal Cell Carcinoma, Blockbusters, Breast Cancer, Checkpoint Inhibitors, Clinical Data, Clinical Trial Endpoints, Clinical Trials, EGFR tyrosine kinase inhibitors (TKI), European Society for Medical Oncology (ESMO), Interim Data, MD Anderson Cancer Center, Melanoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic non-small cell lung cancer, Non-Small Cell Lung Cancer (NSCLC), Overall Survival (OS), R&D, Renal Cell Carcinoma (RCC), Therapeutics, TumorsNumerous companies presented clinical trial data and updates at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
FRANKFURT (Reuters) – AstraZeneca’s top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, […]
Immunomedics drug Trodelvy extends survival in breast cancer patients
Accelerated Approval, Antibody-Drug Conjugates (ADCs), Boxed Warning, Business, Cancer Cells, Clinical Trials, Deals, European Society for Medical Oncology (ESMO), FDA, Metastatic Triple-Negative Breast Cancer (mTNBC), R&D, TherapeuticsImmunomedics Inc.’s cancer drug Trodelvy, which received accelerated U.S. regulatory approval in April 2020, extended survival time in previously treated patients with an advanced form of breast cancer in a clinical trial.